Colombia vs Trinidad and Tobago: Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage
Colombia
91.0%
in 2024
Trinidad and Tobago
91.0%
in 2024
Colombia rank
52nd
Trinidad and Tobago rank
52nd
Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage over time
- Colombia
- Trinidad and Tobago
How they compare
Colombia currently reports 91.0% against 91.0% in Trinidad and Tobago, a difference of 0.0%.
The two have swapped places 1 time across 13 shared years of data; in 2012 it was Colombia ahead.
Colombia ranks 52nd and Trinidad and Tobago ranks 52nd of 146 countries.
Across the 2 decades both report, Colombia averaged higher in 1 and Trinidad and Tobago in 1.
Head to head by decade
| Decade | Colombia | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 89.8% | 85.5% | 4.2% | Colombia |
| 2020s | 87.8% | 93.6% | 5.8% | Trinidad and Tobago |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage, Colombia or Trinidad and Tobago?
- Colombia, at 91.0% against 91.0% in Trinidad and Tobago as of 2024.
- What is the difference in pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage between Colombia and Trinidad and Tobago?
- 0.0%, with Colombia ahead.
- How many years of comparable data are there for Colombia and Trinidad and Tobago?
- 13 years are reported by both, from 2012 to 2024.
- How do Colombia and Trinidad and Tobago rank globally for pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage?
- Colombia ranks 52nd and Trinidad and Tobago ranks 52nd of 146 countries.
- Where does this data come from?
- WHO & UNICEF (2025); UN, World Population Prospects (2024) – processed by Our World in Data, published as Pneumococcal vaccine vs. diphtheria-tetanus-pertussis vaccine coverage. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Share of one-year-olds who have had the third dose of the pneumococcal conjugate vaccine in a given year.